Get the Stockscreener App
8.67
0.12%
-0.010
After Hours:
8.76
0.09
+1.04%
Kazia Therapeutics Limited Adr stock is traded at $8.67, with a volume of 23,083.
It is down -0.12% in the last 24 hours and up +28.44% over the past month.
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
See More
Previous Close:
$8.68
Open:
$8.82
24h Volume:
23,083
Relative Volume:
0.02
Market Cap:
$9.69M
Revenue:
-
Net Income/Loss:
$-13.52M
P/E Ratio:
-11.72
EPS:
-0.74
Net Cash Flow:
$-10.03M
1W Performance:
+2.42%
1M Performance:
+28.44%
6M Performance:
+15.60%
1Y Performance:
-45.86%
1-Day Range:
$8.4177
$8.99
1-Week Range:
$7.40
$8.99
52-Week Range:
$2.86
$39.05
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
Name
Kazia Therapeutics Limited Adr
Sector
Industry
Phone
01161298780088
Address
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Compare KZIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
8.67 | 9.70M | 0 | -13.52M | -10.03M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | Maxim Group | Buy |
| Oct-14-21 | Initiated | Maxim Group | Buy |
| Jan-05-21 | Initiated | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr Stock (KZIA) Latest News
Novogen Limited (NASDAQ:KZIA) Sees Large Growth in Short Interest - Defense World
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market - The Manila Times
Kazia Therapeutics raises US$2m via discounted private placement to fund trials | KZIA SEC FilingForm 6-K - Stock Titan
Kazia Therapeutics Announces At the Market Offering Agreement - The Globe and Mail
Kazia Therapeutics starts US$1.9M ATM ADS program; CEO exits board | KZIA SEC FilingForm 6-K - Stock Titan
Glioblastoma Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - Barchart.com
Novogen (NASDAQ:KZIA) Raised to “Sell” at Wall Street Zen - ETF Daily News
Analysts Issue Forecasts for Novogen FY2025 Earnings - Defense World
Novogen (NASDAQ:KZIA) Upgraded by HC Wainwright to Strong-Buy Rating - Defense World
Novogen (NASDAQ:KZIA) Rating Increased to Strong-Buy at HC Wainwright - Defense World
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - The Globe and Mail
Novogen (NASDAQ:KZIA) Shares Up 39.7% – Should You Buy? - Defense World
Ryde Group files US$100 M shelf; micro-cap float limits near-term raise | KZIA SEC FilingForm 424B3 - Stock Titan
Cancer Innovation Accelerates As Funding Cuts Loom And Biotechs Step Up - Barchart.com
Kazia Therapeutics stock soars after positive early cancer treatment data By Investing.com - Investing.com Nigeria
Kazia Therapeutics stock soars after positive early cancer treatment data - Investing.com Australia
Early Clinical Trial: New Drug Combo Slashes Breast Cancer Cells by 50% in Just 21 Days - Stock Titan
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial - Ariva
Short Interest in Novogen Limited (NASDAQ:KZIA) Declines By 28.0% - Defense World
Biotech Stocks To Add to Your Watchlist – June 11th - Defense World
Kazia Therapeutics (NASDAQ:KZIA) Receives Buy Rating from Maxim Group - Defense World
United States shares lower at close of trade; Dow Jones Industrial Average down 0.00% - Investing.com India
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.00% - Investing.com
SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.00% - Investing.com UK
Kazia’s paxalisib shows promise in breast cancer preclinical study - Investing.com
Kazia’s paxalisib shows promise in breast cancer preclinical study By Investing.com - Investing.com India
Breakthrough: New Drug Paxalisib Successfully Combats Triple-Negative Breast Cancer Resistance in Preclinical Study - Stock Titan
Kazia Therapeutics Reports Half-Year Financials Amidst Ongoing Drug Development - TipRanks
Kazia's Brain Cancer Drug Now Targets Breast Cancer: First Patient Starts Groundbreaking Combination Trial - Stock Titan
Kazia Therapeutics (NASDAQ:KZIA) Stock Price Up 26.7% – What’s Next? - Defense World
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY - Barchart.com
Breast Cancer Treatment Market to reach $72B by 2033 with 9.4% CAGR growth | DataM IntelligenceNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA) - The Globe and Mail
Glioblastoma Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, NICE Approvals, Therapies and Companies by DelveInsight - The Globe and Mail
Kazia Therapeutics Highlights Recent Progress and Provides Business Update – Company Announcement - Financial Times
Kazia's Breakthrough: FDA Green Light for Glioblastoma Trial Plus Major Pipeline Expansion in Breast Cancer - Stock Titan
KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE - marketscreener.com
Barclays PLC Invests $212,000 in Kazia Therapeutics Limited (NASDAQ:KZIA) - Defense World
Kazia Therapeutics (NASDAQ:KZIA) Shares Up 14.1% – Should You Buy? - Defense World
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE - marketscreener.com
KZIAKazia Therapeuti Latest Stock News & Market Updates - Stock Titan
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS - marketscreener.com
United States shares mixed at close of trade; Dow Jones Industrial Average down 1.33% - Investing.com India
Kazia announces voluntary delisting from ASX - marketscreener.com
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA - marketscreener.com
GBM AGILE OPENS TO PAXALISIB IN EUROPE - MarketScreener
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY - marketscreener.com
KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING - marketscreener.com
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium - marketscreener.com
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO - marketscreener.com
Kazia Therapeutics Limited Adr Stock (KZIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):